Free tool
FAERS Monitor: Vtama
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215272 or its brand name (Vtama, Tapinarof). Reports on generic versions are filed under their own applications.
Reports
1,974
Serious
205
10% of reports
Hospitalization
64
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- folliculitis292
- pruritus238
- headache182
- rash152
- dermatitis contact134
- drug ineffective130
- erythema124
- skin burning sensation87
- psoriasis77
- application site erythema63
- off label use63
- application site pruritus62
- application site pain60
- dry skin56
- skin exfoliation54
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 192 |
| 2023 | 664 |
| 2024 | 506 |
| 2025 | 263 |
| 2026 | 341 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,185 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| folliculitisSignal | 292 | 305.2 | 274.0 | 85,815 |
| dermatitis contactSignal | 134 | 126.6 | 107.4 | 16,393 |
| application site pruritusSignal | 62 | 29.2 | 22.8 | 1,657 |
| application site painSignal | 60 | 29.1 | 22.7 | 1,597 |
| application site erythemaSignal | 63 | 25.7 | 20.1 | 1,467 |
| skin burning sensationSignal | 87 | 13.0 | 10.5 | 950 |
| skin exfoliationSignal | 54 | 6.8 | 5.2 | 263 |
| pruritusSignal | 238 | 6.6 | 5.9 | 1,146 |
| erythemaSignal | 124 | 6.4 | 5.4 | 568 |
| psoriasisSignal | 77 | 6.3 | 5.0 | 339 |
| dry skinSignal | 56 | 4.5 | 3.5 | 148 |
| rashSignal | 152 | 3.7 | 3.2 | 305 |
| headacheSignal | 182 | 3.1 | 2.7 | 264 |
| drug ineffective | 130 | 1.1 | 0.9 | 0 |
| off label use | 63 | 0.8 | 0.6 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.